Metabolic dysfunction–associated steatohepatitis (MASH) is now a leading cause of chronic liver disease and is tightly linked to obesity, insulin resistance, and cardiometabolic risk. In the past year, evidence consolidates the position of GLP-1 receptor agonists (GLP-1RAs) and newer incretin multi-agonists as central tools for weight reduction and hepatic improvement in non-cirrhotic MASH, with clear signals on where they excel and where liver-directed agents may be needed. Below, we synthesize the latest randomized evidence, comparative effectiveness, safety, and practical implementation to guide hepatologists and endocrinologists in 2026—and map the likely standard-of-care evolution by 2030.
Pathophysiologic Rationale: Why Incretins Matter in MASH
GLP-1–based agents improve hepatic and cardiometabolic physiology through multiple converging mechanisms:
Robust weight loss is a key mechanism by which GLP-1–based therapies improve MASH, as reductions in body weight decrease hepatic fat influx and adipose-driven lipotoxicity. Newer multi-agonists such as tirzepatide and retatrutide appear to extend this benefit beyond GLP-1 alone by engaging GIP and/or glucagon pathways, thereby further suppressing appetite, increasing energy expenditure, and altering substrate utilization 36168.
Improved insulin sensitivity and glycemic control also contribute importantly to hepatic benefit, since lower insulin resistance reduces de novo lipogenesis and hepatocellular fat accumulation. In clinical trials, GLP-1 receptor agonists significantly reduced HbA1c by 1.30% and body weight by 4.48 kg versus placebo, while also lowering ALT, AST, and GGT, findings that are consistent with reduced hepatic inflammation and injury. 1.
Effects on hepatic lipid handling and inflammation may differ across incretin classes. GLP-1/GIP co-agonism appears mainly to strengthen metabolic and inflammatory pathway benefits, whereas GLP-1/glucagon co-agonism may further enhance hepatic lipid oxidation and fat mobilization; these mechanistic differences are reflected in comparative analyses showing stronger signals for liver fat reduction and fibrosis improvement with certain glucagon-containing co-agonists 26.
Beyond direct hepatic effects, GLP-1–based therapies exert broader extrahepatic benefits by favorably modulating cardiovascular risk factors and potentially improving common MASH comorbidities such as obstructive sleep apnea, chronic kidney disease, and heart failure with preserved ejection fraction, in line with their broader benefits in type 2 diabetes and obesity. Their effects may also extend to behaviors such as reduced alcohol intake, which could in turn lessen an additional contributor to hepatic injury 11.
Clinical Evidence Base in the Past 12 Months
High-quality syntheses and Phase 2/3 data converge on three key conclusions:
- GLP-1RAs achieve MASH resolution and reduce liver fat;
- fibrosis improvement is modest with GLP-1 monotherapy compared with some liver-directed agents;
- efficacy in compensated cirrhosis is limited.
GLP-1RAs (meta-analysis of 13 RCTs; n=1,811): In MASH with F2–F3 fibrosis, GLP-1RAs—especially semaglutide 2.4 mg weekly—significantly increased MASH resolution without fibrosis worsening (pooled OR 3.48) and improved fibrosis by ≥1 stage without MASH worsening (OR 1.79) versus placebo. Liver fat measured by MRI decreased significantly (−4.50% absolute MRI-PDFF). Benefits in compensated cirrhosis (F4) were not observed in the single available RCT (semaglutide 2.4 mg), emphasizing limited utility in advanced disease 1.
Network meta-analysis (29 RCTs; n=9,324 biopsy-proven MASH): Among many agents, multi-agonists ranked highly for MASH resolution and fibrosis improvement. Pegozafermin and survodutide led rankings for both fibrosis improvement and MASH resolution. Tirzepatide also ranked highly for MASH resolution and fibrosis improvement. Among GLP-1RAs, semaglutide and liraglutide were superior to placebo for MASH resolution; semaglutide also significantly improved fibrosis versus placebo, albeit with smaller effect sizes than top-ranked liver-directed agents or multi-agonists 2.
Combination with liver-directed therapy: Adding efruxifermin (FGF21 analog) to background GLP-1RA (semaglutide, dulaglutide, liraglutide) in a 12-week Phase 2b cohort yielded a 65% reduction in hepatic fat fraction versus 10% with placebo, with improvements in noninvasive fibrosis markers and maintained GLP-1RA–mediated weight loss—supporting complementary mechanisms 4.
Imaging biomarkers: A 39-trial NMA ranked agents for MRI-PDFF reduction at 24 weeks; top performers were aldafermin and pegozafermin. Combination therapy (semaglutide + firsocostat) ranked highly for ≥30% PDFF decline at 24 weeks, hinting at synergy with lipid synthesis inhibition pathways 5.
Notably, detailed randomized data on other noninvasive tests (ELF, FAST), MR elastography, and durability after treatment cessation were not found in the retrieved materials.
Evidence Summary (Selected Programs and Syntheses)
Entry summarizes the most policy- and practice-relevant data points from the retrieved materials. Cross-trial comparisons are exploratory given differences in design and populations.
| Program/Analysis | Population | Key Endpoints | Outcomes vs Placebo | Safety Notes |
|---|---|---|---|---|
| GLP-1RAs in MASH (Meta-analysis, 13 RCTs) 1 | MASH; F2–F3 and F4 subsets | MASH resolution; fibrosis improvement; MRI-PDFF; enzymes | MASH resolution OR 3.48; fibrosis improvement OR 1.79; MRI-PDFF −4.50%; reduced ALT/AST/GGT; no histologic benefit in F4 | GI AEs more frequent but mostly mild–moderate |
| Network meta-analysis (29 RCTs) 2 | Biopsy-proven MASH | Fibrosis improvement; MASH resolution | Top-ranked for fibrosis: pegozafermin, cilofexor+firsocostat; GLP-1/GIP (tirzepatide) and GLP-1/glucagon (survodutide) significant. For MASH resolution: pegozafermin, survodutide, tirzepatide highest; semaglutide and liraglutide significant vs placebo | Consistent with class-specific GI profiles |
| Efruxifermin add-on to GLP-1RA (Phase 2b) 4 | T2D + MASH F1–F3 on stable GLP-1RA | Hepatic fat fraction; noninvasive fibrosis markers | HFF −65% vs −10% (12 w); improved fibrosis and metabolic markers; maintained weight loss | Well-tolerated; mild–moderate GI AEs |
| MRI-PDFF reduction (NMA, 39 RCTs) 5 | Steatotic liver disease RCTs | 24-wk PDFF; ≥30% PDFF decline | Top SUCRA at 24 w: aldafermin/pegozafermin; ≥30% PDFF decline: efinopegdutide; semaglutide + firsocostat among top combinations | Class-consistent GI AEs |
| Semaglutide in compensated cirrhosis (F4) 1 | MASH-related cirrhosis | Histology | No significant MASH resolution or fibrosis benefit | GI AEs consistent with class |
Benchmarking Against Non-Incretin Therapies
Resmetirom, a thyroid hormone receptor-β agonist, has demonstrated significant but comparatively modest improvements in MASH resolution and fibrosis versus placebo in Phase 3 programs. Because its mechanism is liver-specific and does not rely on weight loss, it may rank behind the leading incretin multi-agonists for MASH resolution in comparative syntheses, yet it remains an appealing option for leaner phenotypes or in patients whose disease persists despite inadequate weight reduction 2.
FGF21 analogs such as efruxifermin and pegozafermin rank among the most effective therapies for both MASH resolution and fibrosis improvement in network analyses and have also produced substantial reductions in MRI-PDFF. Their complementary mechanisms provide a strong rationale for combination therapy with GLP-1 receptor agonists, a strategy further supported by early add-on data 245.
Lanifibranor, a PPAR pan-agonist, has shown significant benefits for both MASH resolution and fibrosis improvement in patients with F2–F3 disease in Phase 2b studies. However, its clinical use may be limited in some phenotypes by adverse effects such as weight gain and edema 2.
FXR agonists, including obeticholic acid, have achieved fibrosis improvement in clinical studies, but concerns about tolerability—particularly pruritus and increases in LDL cholesterol—have constrained adoption and slowed development across this class 2.
Within the broader comparative network meta-analysis landscape, agents such as pegozafermin, incretin multi-agonists, and resmetirom appear to outperform ACC inhibitors, SGLT2 inhibitors, and pioglitazone on primary histologic endpoints. Although combination strategies that include SGLT2 inhibitors are biologically plausible, results from the planned network meta-analysis evaluating these approaches are not yet available 192.
Overall, incretin-based multi-agonists (tirzepatide, survodutide) and FGF21 analogs occupy the top ranks for MASH resolution and fibrosis improvement, while GLP-1 monotherapy reliably improves MASH resolution—with smaller, but significant, effects on fibrosis—plus broad cardiometabolic benefits 12.
Safety and Risk Management
Class effects: Transient, mild–moderate GI adverse events (nausea, vomiting, diarrhea, constipation) are the most common; dose titration mitigates symptoms 116.
Liver disease nuances: No signal of drug-induced liver injury in the reviewed data. In compensated cirrhosis, lack of histologic benefit suggests disease-stage–driven ceiling effects rather than safety limitations 1.
-
Gallbladder and pancreatitis: Continue vigilance for biliary events and rare pancreatitis as with broader GLP-1 use; underpowered to detect rare events in individual trials 116.
-
Retinopathy: Monitor patients with rapid glycemic improvement for retinopathy progression per diabetes best practice 16.
-
Neuropsychiatric and ENT signals: Pharmacovigilance suggests mixed reporting odds for suicidality—higher for ideation, lower for attempts and completed suicide—without establishing causation. ENT signals (e.g., GERD; taste/smell changes; Bell’s palsy) have been reported in FAERS analyses; clinicians should monitor and report suspected events 912.
Drug–drug interactions: No specific interactions unique to MASH surfaced in the retrieved materials. Co-management with statins, antihypertensives, and antidiabetics follows standard endocrinology/hepatology practice.
Practical Implementation and Access
Dosing and adherence: Weekly injectables are standard; gradual titration improves tolerability and adherence. Oral GLP-1 agents and multi-agonists are in development and may broaden options 16.
Care pathways: Align obesity and T2D indications with hepatology goals—endocrinology and primary care can initiate therapy, with hepatology overseeing liver staging and response assessment 14.
Reimbursement and access:
- Medicare Part D coverage is high for semaglutide and tirzepatide, but prior authorization requirements rose sharply to >80% in late 2023–2024, potentially delaying access and widening disparities 26.
- FDA enforcement actions against compounded/unapproved GLP-1 products underscore safety/quality risks, including dosing errors and improper storage; use approved products and avoid salt forms or unauthorized APIs 212223.
Regulatory and Pipeline Outlook (2026–2030)
EMA
The CHMP recommended conditional approval of semaglutide (Kayshild) for non-cirrhotic MASH with F2–F3 fibrosis in January 2026—the first GLP-1RA with an EU MASH indication 27.
US/EU
AASLD updated practice guidance (Nov 2025) provides patient selection and monitoring recommendations for semaglutide in MASH, reflecting ESSENCE-era data integration and the broader therapeutic landscape 28. NICE has initiated a technology appraisal for semaglutide in F2–F3 MASH, with comparators including resmetirom and pioglitazone 25.
Multi-agonists and combinations
Pipeline analyses anticipate approvals for cagrilintide+semaglutide, retatrutide, and survodutide over 2026–2027 for obesity/T2D (and potentially MASH), which could further shift practice toward multi-agonists with greater weight loss and hepatic efficacy 2416. Real-world and outcomes data will be crucial to define their role relative to liver-directed therapies 29.
Nomenclature and trial design
The MASLD/MASH framework facilitates cardiometabolic integration in trials and care pathways—likely to strengthen the positioning of incretin therapies with established metabolic benefits in payer decisions and guidelines 14.
Conclusions
GLP-1RAs (especially semaglutide) are appropriate first-line pharmacotherapy for non-cirrhotic MASH patients with obesity and/or T2D to achieve substantial MASH resolution and liver fat reduction, with modest fibrosis improvement and broad cardiometabolic benefits. Evidence indicates limited efficacy in compensated cirrhosis 1214.
Dual and tri-agonists (particularly tirzepatide and GLP-1/glucagon co-agonists) rank among the most effective for MASH resolution and show promising fibrosis signals in comparative syntheses. As these agents gain broader labels in obesity/T2D—and possibly MASH—combination or sequencing with liver-directed therapies (FGF21 analogs, THR-β agonists) will likely become routine for patients with advanced fibrosis or suboptimal monotherapy response 245242728.
With EMA’s conditional semaglutide approval for MASH and anticipated multi-agonist availability, care will increasingly integrate hepatology and cardiometabolic management. Access constraints (PAs), safety vigilance, and avoidance of compounded products remain critical implementation considerations 26212223.
Clinicians should anchor therapy to fibrosis stage and metabolic phenotype, start early in F2–F3 disease, monitor weight and noninvasive liver biomarkers, and escalate to or combine with liver-directed therapies when fibrosis regression is the treatment goal.